The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia
Abstract
Oxytocin has numerous prosocial and antipsychotic-like effects in animals. Prosocial effects of acute intranasal oxytocin administration have also been reported in human subjects. We conducted a randomized, placebo-controlled trial testing the effects of twice daily intranasal oxytocin treatment for 14 days on psychotic symptoms and social cognition in patients with schizophrenia. PANSS scores declined significantly and several social cognition measures improved significantly or nearly significantly in oxytocin (N=11) but not placebo (N=9) recipients. Our results suggest that, in addition to reducing classic psychotic symptoms, oxytocin may diminish certain social cognition deficits that are not improved by current antipsychotic medications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The acute effects of intranasal OT that we found here resemble those found in many human studies, consisting of an increase in pro-social behavior and engagement (specifically time spent in contact in males)(13,15,64–66).”
From Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles (2013) · cites this paper as [15]
In the citing paper
“while some studies among patients with other psychiatric disorders (e.g., autism, alcohol use disorder) have utilized a repeated dosing strategy in the form of 1–3 daily doses, most of these studies are only 8 days or less (Dadds et al., 2014; Guastella et al., 2015; Pedersen et al., 2011).”
From Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: a randomized, placebo-controlled pilot trial (2018) · cites this paper as Pedersen et al., 2011
In the citing paper
“Safety and feasibility of daily dosing has been demonstrated in other human OT studies including those with alcohol-dependent patients (Pedersen et al., 2013), patients with schizophrenia (Pedersen et al., 2011) and individuals with trauma exposure (van Zuiden et al., 2016).”
From Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: a randomized, placebo-controlled pilot trial (2018) · cites this paper as Pedersen et al., 2011
In the citing paper
“Support for the notion that an effect size of d = 0.4 adequately reflects the potential of oxytocin to reduce psychiatric symptoms stems from 2 previous studies on long-term intranasal oxytocin administration in the treatment of positive and negative symptoms in schizophrenia patients [61,97].”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [97]
In the citing paper
“The observed effect sizes were between d = 0.05 - 0.88 [97] and d = 0.24 -.74 (for most outcomes around d = 0.4) [61], depending on the outcome measure.”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [97]
In the citing paper
“Noteworthy, oxytocin treatment greatly reduced anxiety symptoms in schizophrenic patients (d = 0.62) [97].”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [97]
In the citing paper
“Previous research has shown modest effects of OT on people suffering from social deficits, such as autism spectrum disorders (Hollander et al., 2007), schizophrenia (Pedersen et al., 2011) or social anxiety disorder (Guastella et al., 2009).”
From OT promotes closer interpersonal distance among highly empathic individuals (2015) · cites this paper as Pedersen et al., 2011
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Frith, C., & Frith, U. (2005) · Current Biology · doi:10.1016/j.cub.2005.08.041 · Cited by 3,561
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Fett, A.-K. J., Viechtbauer, W., Dominguez, M.-D.-G., Penn, D. L., van Os, J., & Krabbendam, L. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.07.001 · Cited by 1,833
The Functional Significance of Social Cognition in Schizophrenia: A Review
Couture, S. M. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl029 · Cited by 1,363
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
The human amygdala in social judgment
Adolphs, R., Tranel, D., & Damasio, A. R. (1998) · Nature · doi:10.1038/30982 · Cited by 1,125
Oxytocin: The Great Facilitator of Life
Lee, H.-J., Macbeth, A. H., Pagani, J., & Young, W. S. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.001 · Cited by 1,037
The Human Amygdala in Social Judgment
Adolphs, R., Tranel, D., & Damásio, A. R. (2002) · The MIT Press eBooks · doi:10.7551/mitpress/3077.003.0027 · Cited by 881
Paranoia and self-consciousness.
Fenigstein, A., & Vanable, P. (1992) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.62.1.129 · Cited by 643
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Social cognition in schizophrenia
Green, M. F., Horan, W. P., & Lee, J. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4005 · Cited by 1,159
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 584
Bakermans-Kranenburg, M. J., & van IJzendoorn, M. H. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.34 · Cited by 383
Graustella, A. J., & MacLeod, C. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.01.002 · Cited by 379
Uvnäs-Moberg, K., Handlin, L., & Petersson, M. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2014.01529 · Cited by 351
Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 376
Intranasal Treatment of Central Nervous System Dysfunction in Humans
Chapman, C. D., Frey, W. H., Craft, S., Danielyan, L., Hallschmid, M., Schiöth, H. B., & Benedict, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0915-1 · Cited by 310
Immunohistochemical localization of oxytocin receptors in human brain
Boccia, M. L., Petrusz, P., Suzuki, K., Marson, L., & Pedersen, C. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.048 · Cited by 276
Cochran, D. M., Fallon, D., Hill, M., & Frazier, J. A. (2013) · Harvard Review of Psychiatry · doi:10.1097/hrp.0b013e3182a75b7d · Cited by 267
Bales, K. L., Perkeybile, A. M., Conley, O. G., Lee, M. H., Guoynes, C. D., Downing, G. M., Yun, C. R., Solomon, M., Jacob, S., & Mendoza, S. P. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.025 · Cited by 265
Gonzalez-Liencres, C., Shamay‐Tsoory, S., & Brüne, M. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.001 · Cited by 290
Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules
Fortuna, A. C., Alves, G., Serralheiro, A., Sousa, J., & Falcão, A. C. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.03.004 · Cited by 218
Intranasal oxytocin blocks alcohol withdrawal in human subjects
Pedersen, C. A., Smedley, K. L., Leserman, J., Jarskog, L. F., Rau, S. W., Kampov‐Polevoi, A., Casey, R. L., Fender, T., & Garbutt, J. C. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01958.x · Cited by 196
Self-citationDevelopmental Perspectives on Oxytocin and Vasopressin
Hammock, E. A. D. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.120 · Cited by 184
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181
Wigton, R., Radua, J., Allen, P., Averbeck, B., Meyer-Lindenberg, A., McGuire, P., Shergill, S. S., & Fusar-Poli, P. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130289 · Cited by 179
Nose-to-brain peptide delivery – The potential of nanotechnology
Samaridou, E., & Alonso, M. J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.001 · Cited by 183
Making room for oxytocin in understanding depression
McQuaid, R. J., McInnis, O. A., Abizaid, A. B., & Anisman, H. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.07.005 · Cited by 175
The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia
Javed, A., & Charles, A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00157 · Cited by 158
Tachibana, M., Kagitani-Shimono, K., Mohri, I., Yamamoto, T., Sanefuji, W., Nakamura, A., Oishi, M., Kimura, T., Onaka, T., Ozono, K., et al. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0048 · Cited by 151
Rutigliano, G., Rocchetti, M., Paloyelis, Y., Gilleen, J., Sardella, A., Cappucciati, M., Palombini, E., Dell’Osso, L., Caverzasi, E., Politi, P., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.117 · Cited by 149
“Finally, the results of two recent clinical trials of exogenous OT (intranasal administration; dose: 24 IU twice daily (Pedersen et al., 2011) and 40 IU twice daily (Feifel et al.”
Oxytocin-Augmented Social Cognitive Skills Training in Schizophrenia
Davis, M. C., Green, M. F., Lee, J., Horan, W. P., Senturk, D., Clarke, A. D., & Marder, S. R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.68 · Cited by 149
Yamasue, H., Yee, J. R., Hurlemann, R., Rilling, J. K., Chen, F. S., Meyer-Lindenberg, A., & Tost, H. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3327-12.2012 · Cited by 149
Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis
Keech, B., Crowe, S., & Hocking, D. R. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.09.022 · Cited by 145
Metacognition, Self-Reflection and Recovery In Schizophrenia
Lysaker, P. H., Vohs, J. L., Ballard, R., Fogley, R., Salvatore, G., Popolo, R., & Dimaggio, G. (2013) · Future Neurology · doi:10.2217/fnl.12.78 · Cited by 134
Intranasal oxytocin increases covert attention to positive social cues
Domes, G., Sibold, M., Schulze, L., Lischke, A., Herpertz, S. C., & Heinrichs, M. (2013) · Psychological Medicine · doi:10.1017/s0033291712002565 · Cited by 130
Oxytocin, vasopressin, and the motivational forces that drive social behaviors
Caldwell, H. K., & Albers, H. E. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_390 · Cited by 129
Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders
Rubin, L. H., Carter, C. S., Bishop, J. R., Pournajafi-Nazarloo, H., Drogos, L. L., Hill, S. K., Ruocco, A. C., Keedy, S. K., Reilly, J. L., Keshavan, M. S., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu027 · Cited by 127
Effects of single dose intranasal oxytocin on social cognition in schizophrenia
Davis, M. C., Lee, J., Horan, W. P., Clarke, A. D., McGee, M. R., Green, M. F., & Marder, S. R. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.023 · Cited by 124
Gangadhar, B. N., Jayaram, N., Varambally, S. S., Behere, R. V., Venkatasubramanian, G., Arasappa, R., & Christopher, R. (2013) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.116318 · Cited by 132
Shamay-Tsoory, S. G., Abu-Akel, A., Palgi, S., Sulieman, R., Fischer-Shofty, M., Levkovitz, Y., & Decety, J. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.09.015 · Cited by 123
Koch, S. B. J., van Zuiden, M., Nawijn, L., Frijling, J. L., Veltman, D. J., & Olff, M. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.11.018 · Cited by 123
Montag, C., Brockmann, E.-M., Lehmann, A. I., Müller, D. J., Rujescu, D., & Gallinat, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051882 · Cited by 128
Oxytocin in the socioemotional brain: implications for psychiatric disorders
Kirsch, P. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.4/pkirsch · Cited by 123
Cacciotti-Saija, C., Langdon, R., Ward, P. B., Hickie, I. B., Scott, E. M., Naismith, S. L., Moore, L., Alvares, G. A., Redoblado Hodge, M. A., & Guastella, A. J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu094 · Cited by 119
Sex, Receptors, and Attachment: A Review of Individual Factors Influencing Response to Oxytocin
MacDonald, K. S. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00194 · Cited by 119
Millan, M. J., & Bales, K. L. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.09.012 · Cited by 119
Oxytocin and postpartum depression: Delivering on what's known and what's not
Kim, S., Soeken, T. A., CROMER, S. J., Martinez, S. R., Hardy, L. R., & Strathearn, L. (2013) · Brain Research · doi:10.1016/j.brainres.2013.11.009 · Cited by 121
Cagna, F. D., Fusar‐Poli, L., Damiani, S., Rocchetti, M., Giovanna, G., Mori, A., Politi, P., & Brondino, N. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.1.1 · Cited by 121
Flanagan, J. C., Sippel, L. M., Wahlquist, A., Moran-Santa Maria, M. M., & Back, S. E. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.12.014 · Cited by 117
Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia
Feifel, D., MacDonald, K. S., Cobb, P., & Minassian, A. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.05.018 · Cited by 117
Oxytocin administration enhances controlled social cognition in patients with schizophrenia
Woolley, J. D., Chuang, B., Lam, O., Lai, W., O’Donovan, A., Rankin, K. P., Mathalon, D. H., & Vinogradov, S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.04.024 · Cited by 116
Oxytocin in schizophrenia: a review of evidence for its therapeutic effects
MacDonald, K. S., & Feifel, D. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00634.x · Cited by 117
Brüne, M. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-38 · Cited by 116
Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?
Kucharska‐Pietura, K., & Mortimer, A. M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0047-0 · Cited by 112
A Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia
Feifel, D., Shilling, P. D., & MacDonald, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.025 · Cited by 110
Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
Fusar-Poli, P., Davies, C., Solmi, M., Brondino, N., De Micheli, A., Kotlicka-Antczak, M., Shin, J. I., & Radua, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00764 · Cited by 108
Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia
Modabbernia, A., Rezaei, F., Salehi, B., Jafarinia, M., Ashrafi, M., Tabrizi, M. H., Hosseini, S. M. R., Tajdini, M., Ghaleiha, A., & Akhondzadeh, S. (2012) · CNS Drugs · doi:10.1007/s40263-012-0022-1 · Cited by 107
A brief history of oxytocin and its role in modulating psychostimulant effects
Carson, D. S., Guastella, A. J., Taylor, E. R., & McGregor, I. S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112473788 · Cited by 105
Oxytocin for the treatment of drug and alcohol use disorders
Lee, M. R., & Weerts, E. M. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000258 · Cited by 105
Yuen, K. W., Garner, J. P., Carson, D. S., Keller, J., Lembke, A., Hyde, S. A., Kenna, H. A., Tennakoon, L., Schatzberg, A. F., & Parker, K. J. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.12.012 · Cited by 99
Prosocial effects of oxytocin in two mouse models of autism spectrum disorders
Teng, B. L., Nonneman, R. J., Agster, K. L., Nikolova, V. D., Davis, T. T., Riddick, N. V., Baker, L. K., Pedersen, C. A., Jarstfer, M. B., & Moy, S. S. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.038 · Cited by 98
Social cognitive interventions for people with schizophrenia: A systematic review
Tan, B., Lee, S.-A., & Lee, J. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.06.013 · Cited by 100
Sasayama, D., Hattori, K., Teraishi, T., Hori, H., Ota, M., Yoshida, S., Arima, K., Higuchi, T., Amano, N., & Kunugi, H. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.016 · Cited by 96
Crystal structure of the human oxytocin receptor
Waltenspühl, Y., Schöppe, J., Ehrenmann, J., Kummer, L., & Plückthun, A. (2020) · Science Advances · doi:10.1126/sciadv.abb5419 · Cited by 95
Stavropoulos, K. K. M., & Carver, L. J. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12061 · Cited by 104
New treatment approaches for severe and enduring eating disorders
Treasure, J., Cardi, V., Leppanen, J., & Turton, R. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.007 · Cited by 91
Calcagnoli, F., Kreutzmann, J. C., de Boer, S. F., Althaus, M., & Koolhaas, J. M. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.09.019 · Cited by 96
Alvares, G. A., Quintana, D. S., & Whitehouse, A. J. O. (2017) · Autism Research · doi:10.1002/aur.1692 · Cited by 91
Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients
Jobst, A., Dehning, S., Ruf, S., Notz, T., Buchheim, A., Henning-Fast, K., Meißner, D., Meyer, S., Bondy, B., Müller, N., et al. (2014) · Acta Neuropsychiatrica · doi:10.1017/neu.2014.20 · Cited by 89
Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward
Bradley, E., & Woolley, J. D. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.007 · Cited by 92
Gibson, C. M., Penn, D. L., Smedley, K. L., Leserman, J., Elliott, T., & Pedersen, C. A. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.009 · Cited by 88
Smith, M. J., Horan, W. P., Cobia, D. J., Karpouzian‐Rogers, T., Fox, J. M., Reilly, J. L., & Breiter, H. C. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt084 · Cited by 91
Learning About Oxytocin: Pharmacologic and Behavioral Issues
Chini, B., Leonzino, M., Braida, D., & Sala, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.029 · Cited by 91
OT promotes closer interpersonal distance among highly empathic individuals
Perry, A., Mankuta, D., & Shamay-Tsoory, S. G. (2015) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsu017 · Cited by 86
The many faces of oxytocin: Implications for psychiatry
Zik, J. B., & Roberts, D. L. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.048 · Cited by 91
Potential of Oxytocin in the Treatment of Schizophrenia
Shilling, P. D., & Feifel, D. (2016) · CNS Drugs · doi:10.1007/s40263-016-0315-x · Cited by 84
Oxytocin increases empathy to pain when adopting the other-but not the self-perspective
Abu-Akel, A., Palgi, S., Klein, E., Decety, J., & Shamay-Tsoory, S. (2015) · Social Neuroscience · doi:10.1080/17470919.2014.948637 · Cited by 83
Improving social perception in schizophrenia: The role of oxytocin
Fischer-Shofty, M., Brüne, M., Ebert, A., Shefet, D., Levkovitz, Y., & Shamay‐Tsoory, S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.006 · Cited by 83
Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review
Heringa, S. M., Begemann, M., Goverde, A. J., & Sommer, I. E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.002 · Cited by 82
“Autism-plus” Spectrum Disorders
Cochran, D., Dvir, Y., & Frazier, J. A. (2013) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2013.04.005 · Cited by 84
Self-reported empathy deficits are uniquely associated with poor functioning in schizophrenia
Smith, M. J., Horan, W. P., Karpouzian‐Rogers, T., Abram, S. V., Cobia, D. J., & Csernansky, J. G. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.01.012 · Cited by 81
Lee, M. R., Wehring, H. J., McMahon, R. P., Linthicum, J., Cascella, N., Liu, F., Bellack, A., Buchanan, R. W., Strauss, G. P., Contoreggi, C., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.001 · Cited by 80
Sobota, R., Mihara, T., Forrest, A., Featherstone, R. E., & Siegel, S. J. (2015) · Behavioral Neuroscience · doi:10.1037/bne0000074 · Cited by 80
Muttenthaler, M., Andersson, Å., Vetter, I., Menon, R., Busnelli, M., Ragnarsson, L. K. N., Bergmayr, C., Arrowsmith, S., Deuis, J. R., Chiu, H. S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aan3398 · Cited by 78
Bürkner, P., Williams, D. R., Simmons, T. C., & Woolley, J. D. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx053 · Cited by 82
Peyroux, E., & Franck, N. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00400 · Cited by 79
Role of yoga and mindfulness in severe mental illnesses: A narrative review
Sathyanarayanan, G., Vengadavaradan, A., & Bharadwaj, B. (2018) · International Journal of Yoga · doi:10.4103/ijoy.ijoy_65_17 · Cited by 80
Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment
Goh, K. K., Chen, C.-H., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042146 · Cited by 84
Uhrig, S., Hirth, N., Broccoli, L., von Wilmsdorff, M., Bauer, M., Sommer, C., Zink, M., Steiner, J. H., Frodl, T., Malchow, B., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.04.019 · Cited by 73
Girgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 75
Peled‐Avron, L., Abu-Akel, A. M., & Shamay‐Tsoory, S. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.04.023 · Cited by 79
Rubin, L. H., Connelly, J. J., Reilly, J. L., Carter, C. S., Drogos, L. L., Pournajafi‐Nazarloo, H., Ruocco, A. C., Keedy, S., Matthew, I., Tandon, N., et al. (2015) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2015.10.003 · Cited by 72
Oxytocin and vasopressin: signalling, behavioural modulation and potential therapeutic effects
Rae, M., Lemos Duarte, M., Gomes, I., Camarini, R., & Devi, L. A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15481 · Cited by 72
Effects of Oxytocin on Neural Response to Facial Expressions in Patients with Schizophrenia
Shin, N. Y., Park, H. Y., Jung, W. H., Park, J. W., Yun, J., Jang, J. H., Kim, S. N., Han, H. J., Kim, S.-Y., Kang, D., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.41 · Cited by 69
The effect of oxytocin on attention to angry and happy faces in chronic depression
Domes, G., Normann, C., & Heinrichs, M. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0794-9 · Cited by 73
A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia
Guastella, A. J., Ward, P. B., Hickie, I. B., Shahrestani, S., Hodge, M. A., Scott, E. M., & Langdon, R. A. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.005 · Cited by 69
Oxytocin: Parallel Processing in the Social Brain?
Dölen, G. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12284 · Cited by 65
Rubin, L. H., Carter, C. S., Bishop, J. R., Pournajafi‐Nazarloo, H., Harris, M. S. H., Hill, S. K., Reilly, J. L., & Sweeney, J. A. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.019 · Cited by 65
Theory of mind and its relevance in schizophrenia
Biedermann, F., Frajo-Apor, B., & Hofer, A. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283503624 · Cited by 65
Horta, M., Kaylor, K., Feifel, D., & Ebner, N. C. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.012 · Cited by 63
Oxytocin and vasopressin modulate the social response to threat: a preclinical study
Bowen, M. T., & McGregor, I. S. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000388 · Cited by 63
Effects of a 10-day oxytocin trial in older adults on health and well-being
Barraza, J. A., Grewal, N. S., Ropacki, S., Perez, P., Gonzalez, A., & Zak, P. J. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0031581 · Cited by 61
Hara, Y., Ago, Y., Higuchi, M., Hasebe, S., Nakazawa, T., Hashimoto, H., Matsuda, T., & Takuma, K. (2017) · Hormones and Behavior · doi:10.1016/j.yhbeh.2017.09.013 · Cited by 61
Reversal of social deficits by subchronic oxytocin in two autism mouse models
Teng, B. L., Nikolova, V. D., Riddick, N. V., Agster, K. L., Crowley, J. J., Baker, L. K., Koller, B. H., Pedersen, C. A., Jarstfer, M. B., & Moy, S. S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.025 · Cited by 65
Quintana, D. S., Kemp, A. H., Alvares, G. A., & Guastella, A. J. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00048 · Cited by 66
Frijling, J. L., van Zuiden, M., Koch, S. B., Nawijn, L., Goslings, J. C., Luitse, J. S., Biesheuvel, T. H., Honig, A., Bakker, F. C., Denys, D., et al. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-92 · Cited by 59
Dramatic Improvement in Sexual Function Induced by Intranasal Oxytocin
MacDonald, K. S., & Feifel, D. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02703.x · Cited by 59
Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis
Williams, D. R., & Bürkner, P. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.10.013 · Cited by 58
Intranasal delivery of antipsychotic drugs
Katare, Y. K., Piazza, J. E., Bhandari, J., Daya, R. P., Akilan, K., Simpson, M. J., Hoare, T. R., & Mishra, R. K. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.027 · Cited by 57
Metadata
- Authors
- Pedersen, C. A., Gibson, C. M., Rau, S. W., Salimi, K., Smedley, K. L., Casey, R. L., Leserman, J., Jarskog, L. F., & Penn, D. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Pedersen, Cort A.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 132
- Issue
- 1
- Pages
- 50-53
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W1974375338
- Cited by
- 305
- References
- 29
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 8 · 2023: 13 · 2022: 9 · 2021: 18 · 2020: 9 · 2019: 19 · 2018: 17 · 2017: 25 · 2016: 35 · 2015: 36 · 2014: 34 · 2013: 51 · 2012: 23
- FWCI
- 47.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- National Institute of Mental Health (R01MH093529)
- National Center for Research Resources (UL1RR025747)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- intranasal oxytocin, schizophrenia
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Analysis of Variance, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Oxytocin, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Social Perception, Antipsychotic Agents, Treatment Outcome, Young Adult, Theory of Mind
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
